A small molecule approach to degrade RAS with EGFR repression is a potential therapy for KRAS mutation-driven colorectal cancer resistance to cetuximab

Drugs targeting the epidermal growth factor receptor (EGFR), such as cetuximab and panitumumab, have been prescribed for metastatic colorectal cancer (CRC), but patients harboring KRAS mutations are insensitive to them and do not have an alternative drug to overcome the problem. The levels of β-cate...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Exp Mol Med
Main Authors: Lee, Sang-Kyu, Cho, Yong-Hee, Cha, Pu-Hyeon, Yoon, Jeong-Soo, Ro, Eun Ji, Jeong, Woo-Jeong, Park, Jieun, Kim, Hyuntae, Il Kim, Tae, Min, Do Sik, Han, Gyoonhee, Choi, Kang-Yell
Formato: Artigo
Idioma:Inglês
Publicado em: Nature Publishing Group UK 2018
Assuntos:
Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC6244225/
https://ncbi.nlm.nih.gov/pubmed/30459318
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/s12276-018-0182-2
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados